Literature DB >> 17356097

Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy.

Anirban Choudhury1, Irene Chung1, Andrew D Blann1, Gregory Y H Lip2.   

Abstract

BACKGROUND: Platelet microparticles (PMPs), are procoagulant membrane vesicles that are derived from activated platelets, the levels of which are elevated in patients with hypertension, coronary artery disease (CAD), diabetes, and stroke, all of which are conditions that lead to (and are associated with) atrial fibrillation (AF). We hypothesized the following: (1) PMP levels are elevated in patients with AF compared to levels in both healthy control subjects (ie, patients without cardiovascular diseases who are in sinus rhythm) and disease control subjects (ie, patients with hypertension, CAD, diabetes or stroke, but who are in sinus rhythm); (2) PMP levels correlate with levels of soluble P-selectin (sP-selectin) [a marker of platelet activation]; and (3) PMP levels are related to the underlying factors in patients with AF that contribute to the overall risk of stroke secondary to AF.
METHODS: We performed a case-control study of 70 AF patients, 46 disease control subjects and 33 healthy control subjects. Peripheral venous levels of PMP and sP-selectin were analyzed by flow cytometry and enzyme-linked immunosorbent assay, respectively.
RESULTS: Both AF patients and disease control subjects had significantly higher levels of PMPs (p < 0.001) and sP-selectin (p = 0.001) compared to healthy control subjects, but there was no difference between AF patients and disease control subjects. There was no difference in PMP levels between patients with paroxysmal and permanent AF (p = 0.581), and between those receiving therapy with aspirin and warfarin (p = 0.779). No significant correlation was observed between PMP and sP-selectin levels (p = 0.463), and the clinical characteristics that contribute to increased stroke risk in patients with AF. On stepwise multiple regression analysis in the combined cohort of AF patients plus disease control subjects, the presence/absence of AF was not an independent determinant of PMP and sP-selectin levels.
CONCLUSION: There is evidence of platelet activation (ie, high PMP and sP-selectin levels) in AF patients, but this is likely to be due to underlying cardiovascular diseases rather than the arrhythmia per se.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356097     DOI: 10.1378/chest.06-2039

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue.

Authors:  Licia Polimeni; Ludovica Perri; Mirella Saliola; Stefania Basili; Francesco Violi
Journal:  Intern Emerg Med       Date:  2010-03-03       Impact factor: 3.397

2.  Blood biomarkers in cardioembolic stroke.

Authors:  Teresa García-Berrocoso; Israel Fernández-Cadenas; Pilar Delgado; Anna Rosell; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2010-08

Review 3.  Microparticles and cardiovascular diseases.

Authors:  Christos Voukalis; Eduard Shantsila; Gregory Y H Lip
Journal:  Ann Med       Date:  2019-06-17       Impact factor: 4.709

Review 4.  Complement activation on platelets: implications for vascular inflammation and thrombosis.

Authors:  Ellinor I Peerschke; Wei Yin; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2010-06-01       Impact factor: 4.407

Review 5.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 6.  Peripheral artery disease and atrial fibrillation: a potentially dangerous combination.

Authors:  Francesco Violi; Gregory Y H Lip; Stefania Basili
Journal:  Intern Emerg Med       Date:  2011-06-11       Impact factor: 3.397

Review 7.  Stroke and Death Prediction with the Impact of Vascular Disease in Patients with Atrial Fibrillation.

Authors:  Abhishek Maan; Amir Y Shaikh; Moussa Mansour; Jeremy N Ruskin; E Kevin Heist
Journal:  J Atr Fibrillation       Date:  2012-06-15

8.  Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy?

Authors:  James A Reiffel
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-12

9.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

10.  Expression of complement components and inhibitors on platelet microparticles.

Authors:  Wei Yin; Berhane Ghebrehiwet; Ellinor I B Peerschke
Journal:  Platelets       Date:  2008-05       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.